244 related articles for article (PubMed ID: 12351946)
1. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients.
Antinori A; Giancola ML; Grisetti S; Soldani F; Alba L; Liuzzi G; Amendola A; Capobianchi M; Tozzi V; Perno CF
AIDS; 2002 Sep; 16(14):1867-76. PubMed ID: 12351946
[TBL] [Abstract][Full Text] [Related]
2. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals.
De Luca A; Ciancio BC; Larussa D; Murri R; Cingolani A; Rizzo MG; Giancola ML; Ammassari A; Ortona L
Neurology; 2002 Aug; 59(3):342-7. PubMed ID: 12177366
[TBL] [Abstract][Full Text] [Related]
3. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.
Eggers C; Hertogs K; Stürenburg HJ; van Lunzen J; Stellbrink HJ
AIDS; 2003 Sep; 17(13):1897-906. PubMed ID: 12960822
[TBL] [Abstract][Full Text] [Related]
4. Analysis of correlation between cerebrospinal fluid and plasma HIV-1 RNA levels in patients with neurological opportunistic diseases.
Christo PP; Greco DB; Aleixo AW; Livramento JA
Rev Inst Med Trop Sao Paulo; 2011; 53(4):193-6. PubMed ID: 21915461
[TBL] [Abstract][Full Text] [Related]
5. HIV Type 1 replication in cerebrospinal fluid of patients with AIDS-related non-Hodgkin's lymphoma receiving chemotherapy and antiretroviral therapy.
Giancola ML; Uccella I; Alba L; Lorenzini P; Soldani F; Capobianchi M; Ruco L; Perno CF; Antinori A
AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1091-5. PubMed ID: 14709245
[TBL] [Abstract][Full Text] [Related]
6. Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen.
Polis MA; Suzman DL; Yoder CP; Shen JM; Mican JM; Dewar RL; Metcalf JA; Falloon J; Davey RT; Kovacs JA; Feinberg MB; Masur H; Piscitelli SC
AIDS; 2003 May; 17(8):1167-72. PubMed ID: 12819518
[TBL] [Abstract][Full Text] [Related]
7. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid.
Cinque P; Presi S; Bestetti A; Pierotti C; Racca S; Boeri E; Morelli P; Carrera P; Ferrari M; Lazzarin A
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):377-83. PubMed ID: 11282006
[TBL] [Abstract][Full Text] [Related]
8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era.
Christo PP; Greco DB; Aleixo AW; Livramento JA
BMC Infect Dis; 2007 Dec; 7():147. PubMed ID: 18096083
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy.
Donath M; Wolf T; Stürmer M; Herrmann E; Bickel M; Khaykin P; Göpel S; Gute P; Haberl A; de Leuw P; Schüttfort G; Berger A; Stephan C;
Med Microbiol Immunol; 2016 Dec; 205(6):575-583. PubMed ID: 27469377
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 RNA levels in cerebrospinal fluid and plasma and their correlation with opportunistic neurological diseases in a Brazilian AIDS reference hospital.
Christo PP; Greco DB; Aleixo AW; Livramento JA
Arq Neuropsiquiatr; 2005 Dec; 63(4):907-13. PubMed ID: 16400403
[TBL] [Abstract][Full Text] [Related]
12. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
[TBL] [Abstract][Full Text] [Related]
13. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.
Anderson AM; Muñoz-Moreno JA; McClernon DR; Ellis RJ; Cookson D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Franklin DR; Heaton RK; Grant I; Letendre SL;
J Infect Dis; 2017 Jan; 215(1):105-113. PubMed ID: 27789723
[TBL] [Abstract][Full Text] [Related]
16. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
Spudich S; Lollo N; Liegler T; Deeks SG; Price RW
J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection.
Sinclair E; Ronquillo R; Lollo N; Deeks SG; Hunt P; Yiannoutsos CT; Spudich S; Price RW
J Acquir Immune Defic Syndr; 2008 Apr; 47(5):544-52. PubMed ID: 18362693
[TBL] [Abstract][Full Text] [Related]
18. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of HIV-1 drug resistance in the neurological compartment.
Antinori A; Cingolani A; Giancola ML; Forbici F; De Luca A; Perno CF
Scand J Infect Dis Suppl; 2003; 106():41-4. PubMed ID: 15000582
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
